Regulation of endothelin-converting enzyme-1 (ECE-1) by the calcimimetic R-568
- PMID: 23911580
- DOI: 10.1016/j.phrs.2013.07.006
Regulation of endothelin-converting enzyme-1 (ECE-1) by the calcimimetic R-568
Abstract
Although calcimimetics were developed to block parathyroid hormone synthesis, some reports suggest that they may also reduce blood pressure by unknown mechanisms. Calcimimetic-induced changes in the synthesis of endothelial vasoactive factors could be involved. Wistar rats were treated with the calcimimetic R-568, and systolic blood pressure (SBP) was registered with a tail-cuff sphygmomanometer, the content of endothelial nitric oxide synthase (eNOS) and endothelin-converting enzyme (ECE-1) in tissue was evaluated by immunohistochemistry and Western blot, circulating levels of endothelin-1 (ET-1) were measured by ELISA. R-568 reduced SBP and circulating levels of ET-1, without changes in eNOS expression. In contrast, R-568 increased the lung and vascular content of ECE-1. In order to analyze the mechanisms involved, we studied the effect of R-568 on human endothelial cells. R-568 did not modify neither eNOS protein content nor pre-pro-ET-1 mRNA expression, but increased ECE-1 protein content, and decreased ET-1 synthesis and ECE-1 activity. The inhibition of ECE-1 activity was very strong, similar to the classic ECE inhibitor phosphoramidon, the addition of exogenous zinc restored enzymatic activity. Moreover, the amount of zinc in immunoprecipitated ECE from R-568 treated cells was 3-fold less than in control cells. In conclusion, R-568 inhibits ECE by expelling zinc from the enzyme, with the subsequent decrease in enzymatic activity and reducing circulating levels of ET-1, which may be responsible for the lower SBP observed in R-568-treated rats. This descent would be partially compensated by the increased synthesis of the ECE-1 itself, and by other homeostatic mechanisms that regulate SBP.
Keywords: Blood pressure; CaR; Calcimimetic; DMEM; Dulbecco's Modified Eagle Media; EA; EA.hy926 is a human endothelial cell line; ECE-1; ET-1; Endothelin-1; Endothelin-converting enzyme-1; NO; Nitric oxide; PTH; R-568; SBP; TTBS; Tween Tris buffered saline; calcimimetic R-568; calcium sensing receptor; eNOS; endothelial nitric oxide synthase; endothelin-1; endothelin-converting enzyme-1; nitric oxide; parathyroid hormone; systolic blood pressure.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
The active form of vitamin D, calcitriol, induces a complex dual upregulation of endothelin and nitric oxide in cultured endothelial cells.Am J Physiol Endocrinol Metab. 2014 Dec 15;307(12):E1085-96. doi: 10.1152/ajpendo.00156.2014. Epub 2014 Oct 21. Am J Physiol Endocrinol Metab. 2014. PMID: 25336523
-
Nitric oxide decreases the expression of endothelin-converting enzyme-1 through mRNA destabilization.Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2577-85. doi: 10.1161/ATVBAHA.111.232025. Arterioscler Thromb Vasc Biol. 2011. PMID: 21852564
-
The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1.Br J Pharmacol. 2007 Oct;152(3):313-22. doi: 10.1038/sj.bjp.0707398. Epub 2007 Jul 23. Br J Pharmacol. 2007. PMID: 17643133 Free PMC article.
-
Endothelin Converting Enzyme-1 phosphorylation and trafficking.FEBS Lett. 2012 Jul 30;586(16):2212-7. doi: 10.1016/j.febslet.2012.06.020. Epub 2012 Jun 21. FEBS Lett. 2012. PMID: 22728136 Review.
-
Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis--novel targets for pharmacotherapy in atherosclerosis.Curr Vasc Pharmacol. 2004 Jul;2(3):249-58. doi: 10.2174/1570161043385718. Curr Vasc Pharmacol. 2004. PMID: 15320823 Review.
Cited by
-
Unfavorable Reduction in the Ratio of Endothelin B to A Receptors in Experimental 5/6 Nephrectomy and Adenine Models of Chronic Renal Insufficiency.Int J Mol Sci. 2020 Jan 31;21(3):936. doi: 10.3390/ijms21030936. Int J Mol Sci. 2020. PMID: 32023824 Free PMC article.
-
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.J Hum Hypertens. 2016 Mar;30(3):204-9. doi: 10.1038/jhh.2015.56. Epub 2015 Jun 4. J Hum Hypertens. 2016. PMID: 26040438 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources